Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | CNKSR1 | Q969H4 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126383 | 1.00 | KDM4E (0.46) | KDM4ELMNATHRBATMALDH1A1 | |
| SCHEMBL19172533 | 0.84 | HDAC8 (0.36) | KDM4ELMNASMN1; SMN2HDAC8HDAC6 | |
| SCHEMBL20337173 | 0.83 | KDM4E (0.49) | KDM4ELMNATHRBATMALDH1A1 | |
| SCHEMBL1239519 | 0.81 | ESR1 (0.35) | KDM4ELMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL909055 | 0.81 | CA12 (0.44) | KDM4ELMNAALDH1A1CNKSR1PKM | |
| SCHEMBL1239523 | 0.81 | ESR1 (0.35) | KDM4ELMNAALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL16633690 | 0.81 | KDM4E (0.46) | KDM4ELMNATHRBATMALDH1A1 | |
| SCHEMBL16633691 | 0.81 | KDM4E (0.46) | KDM4ELMNATHRBATMALDH1A1 | |
| SCHEMBL25293885 | 0.79 | KDM4E (0.44) | KDM4ELMNATHRBATMALDH1A1 | |
| SCHEMBL909673 | 0.77 | KDM4E (0.42) | KDM4ELMNATHRBATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2559693-B1 | Polycyclic compound | EISAI R&D MAN CO LTD (JP) | 2014-11-26 | — | — | EP | disclosed |
| EP-2181992-B1 | POLYCYCLIC COMPOUND | EISAI R&D MAN CO LTD (JP) | 2013-05-01 | — | — | EP | disclosed |
| EP-2559693-A1 | Polycyclic compound | Eisai R&D Management Co., Ltd. (JP) | 2013-02-20 | — | — | EP | disclosed |
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | KIMURA TEIJI | 2011-03-17 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065696-A1 | IMIDAZOYL PYRIDINE COMPOUNDS AND SALTS THEREOF | APP, PSEN1, BACE1 | KDM4E 3909/4885LMNA 1027/4885THRB 2828/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | KDM4E 4155/4885LMNA 899/4885THRB 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.